SCHEMBL122819

SCHEMBL122819

NC(=O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.52
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
USP2 O75604 1/20 0.48
SLCO1B1 Q9Y6L6 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PGD P52209 1/20 0.39
KDM4E B2RXH2 2/20 0.36
TGFBR1 P36897 1/20 0.32
OR51E2 Q9H255 1/20 0.32
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4728437 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL4638447 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL2126263 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL7151302 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL1591176 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL6665411 1.00 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL1569332 0.92 PDE4A (0.62) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL5268306 0.92 PDE4A (0.62) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL2912046 0.92 PDE4A (0.62) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL20576207 0.92 PDE4A (0.62) PDE4ALMNAL3MBTL1USP2SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646194-A1 KETO ACID BIOPOLYMERS AND POLYOL KETO ESTERS AND USES THEREOF Atossa Therapeutics, Inc. (US) 2025-11-12 EP claimed
WO-2024148030-A1 KETO ACID BIOPOLYMERS AND POLYOL KETO ESTERS AND USES THEREOF ATOSSA THERAPEUTICS, INC. (US) 2024-07-11 WO claimed
WO-2018106546-A1 METHODS OF DETECTION OF ANTIBIOTIC-RESISTANT BACTERIA SILVER LAKE RESEARCH CORPORATION (US) 2018-06-14 WO claimed
US-20180156796-A1 Methods of Detection of Antibiotic-Resistant Bacteria SILVER LAKE RESEARCH CORPORATION (US) 2018-06-07 US claimed
US-20260115279-A1 Methods for Isolation of Lipid-Disc Compositions and Uses Thereof VIB VZW (BE) 2026-04-30 US disclosed
US-12593839-B2 Fabric care composition comprising a mixture of cationic biocide, functionalized alkylpoyglycoside, and sulfolaurate salt BROADOUS SR TIMOTHY (US) 2026-04-07 US disclosed
US-12544435-B2 Neisserial surface protein a (NSPA) variants and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-02-10 US disclosed
WO-2025264672-A1 INHIBITORS OF MOBILIZED COLISTIN RESISTANCE ENZYME (MCR-1) AND METHODS OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2025-12-26 WO disclosed
EP-4658292-A1 PRODUCTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF PSEUDOMONAS INFECTIONS The Administrators of The Tulane Educational Fund (US) 2025-12-10 EP disclosed
EP-4646194-A1 KETO ACID BIOPOLYMERS AND POLYOL KETO ESTERS AND USES THEREOF Atossa Therapeutics, Inc. (US) 2025-11-12 EP disclosed
WO-2024163916-A9 PRODUCTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF PSEUDOMONAS INFECTIONS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2025-07-17 WO disclosed
US-20250154206-A1 Factor H Binding Protein Variants and Methods of Use Thereof CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND 2025-05-15 US disclosed
EP-0466838-A1 NOVEL LIPID A DERIVATIVES AND USES THEREFOR WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1992-01-22 EP disclosed
WO-1992000101-A1 IMPROVED ADJUVANTS AND VACCINES EMORY UNIVERSITY (US) 1992-01-09 WO disclosed
US-5041427-A Protection Against Gramnegative Endotoxin WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1991-08-20 US disclosed
WO-1991001134-A1 NOVEL LIPID A DERIVATIVES AND USES THEREFOR WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1991-02-07 WO disclosed
EP-0143840-B1 MONOSACCHARIDE COMPOUNDS HAVING IMMUNOSTIMULATING ACTIVITY WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1990-08-29 EP disclosed
EP-0143840-A4 MONOSACCHARIDE COMPOUNDS HAVING IMMUNOSTIMULATING ACTIVITY. WISCONSIN ALUMNI RES FOUND (US) 1986-02-13 EP disclosed
EP-0143840-A1 MONOSACCHARIDE COMPOUNDS HAVING IMMUNOSTIMULATING ACTIVITY. WISCONSIN ALUMNI RES FOUND (US) 1985-06-12 EP disclosed
WO-1984004526-A1 MONOSACCHARIDE COMPOUNDS HAVING IMMUNOSTIMULATING ACTIVITY WISCONSIN ALUMNI RES FOUND (US) 1984-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12593839-B2 Fabric care composition comprising a mixture of cationic biocide, functionalized alkylpoyglycoside, and sulfolaurate salt CUTA, MGAM, PLOD3 PDE4A 1152/4885LMNA 857/4885L3MBTL1 885/4885
US-20260115279-A1 Methods for Isolation of Lipid-Disc Compositions and Uses Thereof STT3B, DDOST, PLTP PDE4A 1422/4885LMNA 989/4885L3MBTL1 851/4885
US-12544435-B2 Neisserial surface protein a (NSPA) variants and methods of use thereof CFH, ASNS, PSPH PDE4A 3334/4885LMNA 797/4885L3MBTL1 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.